CFPA Home Page
QuickJump
 
               
Browse By Industry
SummaryCourse DirectoryTuitionAccreditationsVenueOfferings
 

Course offering number:0903-407

Course ID:
587
Join Our
Mailing List
Email:


U.S. FDA Drug Development and Compliance
March 23-25, 2009
New Brunswick, NJ

Mary L. Richardson; Vice President Regulatory Affairs, Mission Pharmacal Company

Mary L. Richardson is currently Vice President Regulatory Affairs at Mission Pharmacal Company. She oversees all the company’s prescription and OTC drugs, medical devices and dietary supplement production for domestic and international regulatory operations to assure compliance with all applicable requirements. Prior to this industry position, Ms. Richardson worked for twenty-one years with FDA, beginning in the New Jersey district office as a consumer safety officer. She served in the Commissioner’s Office of Legislative Affairs in both the congressional oversight areas of drugs and foods and the legislative section which develops and analyzes pending legislation affecting FDA. Ms. Richardson held the position of Deputy Director in the Office of Drug Compliance in the Division of Drug Labeling Compliance for prescription and OTC drugs and as Deputy in the Division of Scientific Investigations, directing FDA activities in the bio research monitoring programs.

Gary L. Yingling, Esq.; Partner, K&L Gates

Gary L. Yingling, Esq. is a Partner with the law firm of K&L Gates. Prior to entering private practice he was, for nine years, President of the Food and Drug Law Institute. Mr. Yingling served in government for ten years, primarily in FDA’s Office of General Counsel as a trial attorney and, later, as Associate Chief Counsel for Veterinary Medicine and Deputy Chief Counsel for Administration. He also served as Director of FDA’s Over-the-Counter Drug Review. Mr. Yingling received his B.S. in Pharmacy from the University of North Carolina, an M.S. in Pharmacology from Purdue University, and his law degree from Emory University. He is counsel to the International Society for Regulatory Toxicology and Pharmacology, is Editor of the Guide to Good Clinical Practices, and serves on the Editorial Board of both the Clinical Research Practices and Drug Regulatory Affairs and Regulatory Toxicology and Pharmacology journals